Monitoring of Epstein?Barr virus load in patients after allogeneic hematopoietic stem cell transplantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060057" target="_blank" >RIV/00216224:14110/12:00060057 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/12:#0001898

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s15010-012-0262-5" target="_blank" >http://dx.doi.org/10.1007/s15010-012-0262-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s15010-012-0262-5" target="_blank" >10.1007/s15010-012-0262-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring of Epstein?Barr virus load in patients after allogeneic hematopoietic stem cell transplantation

Popis výsledku v původním jazyce

Based on our results, we recommend the weekly monitoring of patients for at least 3 months after HSCT (2 out of 4 patients with EBV-associated disease passed the cut-off at week 11) and longer in patients with GVHD, due to the rapid progression of EBV infection, particularly in patients who develop clinical symptoms (lymphadenopathy, hepatosplenomegaly, or organ manifestations) related to EBV disease according to the European Conference on Infections in Leukemia (ECIL) 2011 guidelines. EBV reactivationoccurred in some of the patients suffering fromGVHDin this cohort, but did not require clinical intervention unless the copy numbers were steadily increasing. A stable EBV viral load1,000 copies/lg DNA temporarily occurred in some patients after HSCT; however, clinical symptoms of EBV infection did not develop and they did not require therapeutic intervention.

Název v anglickém jazyce

Monitoring of Epstein?Barr virus load in patients after allogeneic hematopoietic stem cell transplantation

Popis výsledku anglicky

Based on our results, we recommend the weekly monitoring of patients for at least 3 months after HSCT (2 out of 4 patients with EBV-associated disease passed the cut-off at week 11) and longer in patients with GVHD, due to the rapid progression of EBV infection, particularly in patients who develop clinical symptoms (lymphadenopathy, hepatosplenomegaly, or organ manifestations) related to EBV disease according to the European Conference on Infections in Leukemia (ECIL) 2011 guidelines. EBV reactivationoccurred in some of the patients suffering fromGVHDin this cohort, but did not require clinical intervention unless the copy numbers were steadily increasing. A stable EBV viral load1,000 copies/lg DNA temporarily occurred in some patients after HSCT; however, clinical symptoms of EBV infection did not develop and they did not require therapeutic intervention.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Infection

ISSN

0300-8126

e-ISSN

—

Svazek periodika

40

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

5

Strana od-do

583-587

Kód UT WoS článku

000309340400017

EID výsledku v databázi Scopus

—